# Phase II AK Study in Organ Transplant Patients

> **NCT00829192** · PHASE2 · UNKNOWN · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 200 (estimated)

## Conditions studied

- Actinic Keratoses
- Carcinoma, Squamous Cell
- Organ Transplant Recipients

## Interventions

- **DRUG:** Afamelanotide (CUV1647)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00829192
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-11
- **Primary completion:** 2012-07
- **Final completion:** 2012-08
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2010-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00829192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00829192, "Phase II AK Study in Organ Transplant Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00829192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*